pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,945 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1185Endpoints903BioPharma Dive348BioSpace317Fierce Biotech302onclive165raps107globenewswire health
therapy area
allOncology7784Rare Disease1891Cardiology1781Immunology1514Hematology1329Vaccines1207Pulmonology
  • Madrigal's Rezdiffra sales top forecasts as Gilead announces job cuts
    Madrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen. The outperformance highligh…
    Endpoints · 4mo agoEarningsNeutral↗ source
  • Former Orbital scientists launch ParcelBio with $13 million seed round to boost mRNA therapy durability
    Two former Orbital Therapeutics scientists, Chris Carlson and David Weinberg, have founded a new company called ParcelBio. The startup aims to address a technical limitation that has hindered the…
    Endpoints · 4mo agoDealPositive↗ source
← prev
page 108 of 118
next →
73
fda recalls70
fda medwatch60
fda press38
1203
Psychiatry & CNS870
Ophthalmology505
Pain483
Endocrinology & Metabolism483
Infectious Disease450
  • Experts preview top HR+ and HER2+ breast cancer abstracts ahead of ASCO 2026
    Preparations are under way for the 2026 ASCO Annual Meeting, and breast cancer updates are generating strong interest among clinicians. Leading oncologists including Dr. Yara Abdou of UNC, Dr. VK…
    onclive · 4mo agoNeutral↗ source
  • PhRMA launches seven-figure ad campaign against 340B drug discount program
    PhRMA, the leading pharmaceutical lobbying group, announced a new advertising push aimed at the federal 340B drug discount program. The campaign, described as a seven-figure effort, is set to begi…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Phase 3 MANEUVER trial shows pimicotinib improves response and pain in advanced TGCT, supporting FDA NDA acceptance
    The phase 3 MANEUVER study evaluated pimicotinib in patients with advanced diffuse tenosynovial giant cell tumor. The trial compared the oral agent to placebo and collected both clinical and patien…
    onclive · 4mo agoPositive readoutPositive↗ source
  • BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidate
    BeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
    Endpoints · 4mo agoNegative↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 4mo agoNeutral↗ source
  • Higher PD-L1 levels linked to poorer outcomes in EGFR-mutated NSCLC treated with first-line osimertinib
    Dr. Jonathan Wennan Lee, a chief hematology/oncology fellow at Weill Cornell Medicine, discussed the emerging role of PD-L1 as a predictive biomarker for first-line osimertinib resistance in EGFR-m…
    onclive · 4mo agoNegative readoutNeutral↗ source
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 4mo agoNeutral↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 4mo agoNeutral↗ source
  • Disease Assessment and Mutational Testing in Progressive CLL
    Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.
    onclive · 4mo ago↗ source
  • Clinical Scenario Presentation and Treatment Approach for Progressive Disease
    Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.
    onclive · 4mo ago↗ source
  • Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
    Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.
    onclive · 4mo ago↗ source
  • Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026
    SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.
    onclive · 4mo ago↗ source
  • HHS tackles ‘overmedication’
    The cruise ship hantavirus outbreak, 988 staffing problems, and more health news from Morning Rounds
    STAT · 4mo ago↗ source
  • CellCentric raises $220M to get multiple myeloma pill to market
    CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…
    Endpoints · 4mo ago↗ source
  • Bayer to buy Perfuse Therapeutics for $300M upfront
    Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…
    Endpoints · 4mo ago↗ source
  • Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
    A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…
    Endpoints · 4mo ago↗ source
  • Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care
    Ambiguous loss is at the heart of the dementia illness experience.
    STAT · 4mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants to make a stink
    “They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.
    STAT · 4mo ago↗ source
  • STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
    Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
    STAT · 4mo ago↗ source
  • STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations
    Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change health care are reasonable, but also self-serving, experts say.
    STAT · 4mo ago↗ source
  • Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
    The psychedelics field is getting what it has long wanted. Now it has to step up.
    STAT · 4mo ago↗ source